Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: Do we need a better mouse trap?

Journal of Clinical Oncology

Volumn 22, Issue 15, 2004, Pages 2975-2977

  Dancey, Janet E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PANITUMUMAB; MONOCLONAL ANTIBODY;

ACNE; ADVANCED CANCER; AUTOCRINE EFFECT; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DRUG INHIBITION; EDITORIAL; HUMAN; KIDNEY CARCINOMA; METASTASIS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; CHEMISTRY; DRUG ANTAGONISM; IMMUNOLOGY; KIDNEY TUMOR; NOTE;

ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 4143058243     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.934     Document Type: Editorial

References (24)

1. Gattinoni L, Alu M, Ferrari L, et al: Renal cancer treatment: A review of the literature. Tumori 89:476-484, 2003
2. Campbell SC, Flanigan RC, Clark JI: Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol 4:363-372, 2003
3. Gomella LG, Anglard P, Sargent ER, et al: Epidermal growth factor receptor gene analysis in renal cell carcinoma. J Urol 143:191-193, 1990
4. Hofmockel G, Riess S, Bassukas ID, et al: Epidermal growth factor family and renal cell carcinoma: Expression and prognostic impact. Eur Urol 31:478-484, 1997
5. Ishikawa J, Maeda S, Umezu K, et al: Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma. Int J Cancer 45:1018-1021, 1990
6. Petrides PE, Bock S, Bovens J, et al: Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res 50:3934-3939, 1990
7. Everitt JI, Walker CL, Goldsworthy TW, et al: Altered expression of transforming growth factor-alpha: An early event in renal cell carcinoma development. Mol Carcinog 19:213-219, 1997
8. Price JT, Wilson HM, Haites NE: Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer 32A:1977-1982, 1996
9. Asakuma J, Sumitomo M, Asano T, et al: Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. J Urol 171:897-902, 2004
10. Prewett M, Rothman M, Waksal H, et al: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4:2957-2966, 1998
11. Rowinsky EK, Schwartz GH, Gollob JA, et al: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003-3015, 2004
12. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
13. Drucker B, Bacik J, Ginsberg M, et al: Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 21:341-345, 2003
14. Motzer RJ, Amato R, Todd M, et al: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21:99-101, 2003
15. Elhilali MM, Cleave M, Fradet Y, et al: Placebo-associated remissions in a multicentre, randomized, double-blind trial of Interferon gamma-1b for the treatment of metastatic renal cell carcinoma: The Canadian Urologic Oncology Group. BJU Int 86:613-618, 2000
16. Gleave ME, Elhilali M, Fradet Y, et al: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma: Canadian Urologic Oncology Group. N Engl J Med 338:1265-1271, 1998
17. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
18. Yao M, Yoshida M, Kishida T, et al: VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94:1569-1575, 2002
19. Kondo K, Yao M, Yoshida M, et al: Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 34:58-68, 2002
20. de Paulsen N, Brychzy A, Fournier MC, et al: Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(V-) clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivajion and tumorigenesis. Proc Natl Acad Sci U S A 98:1387-1392, 2001
21. Gunaratnam L, Morley M, Franovic A, et al: Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 278:44966-44974, 2003
22. Perera AD, Kleymenova EV, Walker CL: Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin Cancer Res 6:1518-1523, 2000
23. Viloria-Petit A, Crombet T, Jothy S, et al: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101, 2001
24. Ciardiello F, Bianco R, Caputo R, et al: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10:784-793, 2004